Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Public ClinicalTrials.gov record NCT02586233. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Study identification
- NCT ID
- NCT02586233
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Daiichi Sankyo
- Industry
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Interventions
- DS-1040b Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2015
- Primary completion
- Aug 12, 2019
- Completion
- Aug 12, 2019
- Last update posted
- Sep 8, 2020
2015 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama USA Health System | Mobile | Alabama | 36604 | — |
| UCLA Medical Center Stroke Network | Los Angeles | California | 90024 | — |
| UC Health Memorial Hospital | Colorado Springs | Colorado | 80909 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Kentucky Chandler Medical Center | Lexington | Kentucky | 40536 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| JFK Neuroscience Institute | Edison | New Jersey | 08820 | — |
| Icahn School Medicine at Mount Sinai | New York | New York | 10029 | — |
| Duke University Health System | Durham | North Carolina | 27710 | — |
| OSU - Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health Sciences University Hospital | Portland | Oregon | 97239 | — |
| Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Palmetto Health, USC School of Medicine | Columbia | South Carolina | 29203 | — |
| Chattanooga Center for Neurologic Research | Chattanooga | Tennessee | 37403 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02586233, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2020 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02586233 live on ClinicalTrials.gov.